<DOC>
	<DOCNO>NCT01063283</DOCNO>
	<brief_summary>The purpose study see high dose bevacizumab take safely patient change dose bevacizumab effect blood pressure .</brief_summary>
	<brief_title>Dose Escalation Bevacizumab With Ambulatory Blood Pressure Monitoring Patients With Advanced Non-squamous NSCLC</brief_title>
	<detailed_description>Carboplatin pemetrexed FDA approve chemotherapy agent patient advance non squamous non small cell lung cancer . Bevacizumab also FDA approve lung cancer , combination three drug promise . The doctor direct research want learn well personalize drug dose bevacizumab identify people could safely take high dose drug .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must histologically cytologically confirm , newly diagnose Stage IIIB , stage IV , recurrent nonsquamous NSCLC receive chemotherapy . Patients must complete radiation therapy 2 week prior enrollment . Patients may receive adjuvant therapy , provide regimen include one study agent . Patients must measurable disease , define least one lesion accurately measure least one dimension . Age &gt; 18 year . â€¢Life expectancy great 4 month . ECOG performance status 0 1 Patients must normal organ marrow function Patients anticoagulation allow . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Ability understand willingness sign write informed consent document . DiseaseSpecific Patients receive prior chemotherapy ( set recurrent disease , original adjuvant therapy ) Patients may receive investigational agent . Patients histologic evidence predominantly squamous lung cell cancer General Medical Exclusions Inability comply study and/or followup procedure Malignancy superficial basal cell superficial squamous skin carcinoma situ cervix within last five year BevacizumabSpecific Exclusions Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Known CNS disease , except treat brain metastasis . Significant vascular disease within 6 month prior Day 1 History hemoptysis within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History diverticulitis , abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria demonstrate UPC ratio 1.0 screen Known hypersensitivity component bevacizumab Pregnancy ( positive pregnancy test ) lactation . Mixed tumor categorize predominant cell type unless small cell element present . Uncontrolled intercurrent illness include , ongoing active infection psychiatric illness/social situation would limit compliance study requirement . Any unstable condition opinion investigator likely interfere collection accurate blood pressure measurement data . HIVpositive patient combination antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Non-squamous Non-Small Cell Lung Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Ambulatory Blood Pressure Monitoring</keyword>
</DOC>